Recorded fact · drug.label_indication
drug.label_indication for ocrelizumab|multiple-sclerosis
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact e4aaa520 resolves to.
The record
| Fact id | e4aaa520bbd1ae7825a88ba0 |
|---|---|
| Entity | drug: ocrelizumab|multiple-sclerosis |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260514 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 6d1c3614cef5d4a3e732350568ed458745b4cb02a6e5b92f4169767a9fbb65a5.
The value
{
"ingredient": "Ocrelizumab",
"conditionId": "multiple-sclerosis",
"conditionName": "Multiple Sclerosis",
"matchedAlias": "multiple sclerosis",
"context": "indication",
"brand": "OCREVUS",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "9da42362-3bb5-4b83-b4bb-b59fd4e55f0d",
"labelEffectiveTime": "20260514",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: d0819cbaf62e1532803cb99a8222104e2821793cc6c1a1c6734d45c55219821a.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.